BioFunding

EC launches bioeconomy strategy

06.03.2012

A Brussels – The European Commission is boosting its investments and policy activities to foster sustainability. “Europe needs to make the transition to a post-petroleum economy,” said Máire Geoghegan-Quinn in Brussels. In mid-February, the Research Commissioner unveiled the bloc’s action plan for making the bioeconomy a reality by 2020. “We must drive the transition from a fossil-based to a bio-based society, with research and innovation as a motor,” she stated. “This is good for our environment, our food and energy security, and for Europe’s competitiveness for the future.”
The promise of a more efficient use of bio­degradable waste-streams and other bio­mass to produce foods, chemicals or energy is high, according to Commission estimates (see p. 3). Policymakers say by 2025 they expect a a10 return on each euro now being invested in EU-funded bio­economy research.
The action plan, entitled “Innovating for Sustainable Growth: a Bio­economy for Europe”, recommends boosting R&D investment and technology transfer as the most important priorities. The Commission intends to sink a4.7bn into bio­economy research within its Horizon2020 innovation programme (see EuroBiotechNews 11-12/2011), an investment that has been warmly welcomed by biotech industry stakeholders. “This is a milestone for Europe and the Europeans,” stressed industrial biotech expert Lars Hansen from the bio-industries association EuropaBio, who pointed to the need for additional “support of the member states to make the bioeconomy an EU success story.” Further money will be pumped in via national bioeconomy strategies that have been already been kicked-off in Germany, the Netherlands, Ireland, Finland and Denmark. Additionally, the Commission aims to create Private­Public Partnerships to trigger industry investments.
A second pillar in the agenda is improving the biomass value chain by boosting biomass production, establishing logistics to secure biomass supply and improving its conversion into value-added products in industrial-scale biorefineries. Additionally, the Commission announced it will support communication initiatives aimed at informing consumers about the benefits of bio-based products.

Measures remain vague

However, some industry representatives said they had hoped for more specific support from policymakers. “We had hoped for more concrete measures for bio­plastics to be integrated into the strategy,” said Andy Sweetman, head of European Bioplastics. “What we need are strong measures to support the market development of bio­plastics products.” Kaare Riis Nielsen, director for European affairs at Danish enzyme maker Novozymes, criticised the lack of clear action to support the adoption of second-generation biofuels made from lignocellulose. “Companies will go to the US and China if nothing happens in the policy environment. We need clear political leadership and long-term, stable market conditions,” he said.
According to the Commission, implementation of the bioeconomy in Europe will be dependent on getting all of the involved parties in one boat. Progress will be measured with the help of a newly established Bioeconomy Observatory and Bioeconomy Panel.

Politics / Law

23.03.2012

Brussels/Strasbourg – Health claims are set to be drastically limited in the EU. On Wednesday 21 March the Environment Committee of the European Parliament confirmed a proposal of the European Commission to prohibit 1,600 health...

Politics / Law

15.03.2012

Parma/Stockholm – Foodborne bacteria such as Salmonella and Campylobacter are becoming more and more resistant to antimicrobial drugs, according to a joint report published by the European food watchdog EFSA and the European...

BioFunding

09.03.2012

In mid-February, scientists and entrepreneurs from nine EU countries met at the Center for Genomic Regulation (CRG) in Barcelona to launch the 4DCellFate project. Positioned within the FP7 Programme, the consortium will receive...

BioFunding

09.03.2012

Brussels – The EU’s Innovative Medicines Initiative (IMI) will establish the European Lead Factory, an EU-wide public-private partnership aiming to facilitate drug discovery efforts. The Lead Factory will comprise a...

Editorial

07.03.2012

T    he societal and economic challenges facing Europe and the world are complex and interconnected. The Bioeconomy Strategy and Action Plan “Innovating for Sustainable Growth: a Bioeconomy for Europe”, which was adopted by the...

Tech Review

07.03.2012

Intellectual Property (IP) is without question one of the most vital aspects of any bio­tech venture, a key and undisputed factor for success. However, most bio­tech companies are still incapable of unlocking the value of their...

Clinical Trial

07.03.2012

Schlieren – Swiss Cytos Biotechnology Ltd. has been authorised to restructure a convertible bond by Canton of Zurich authorities. The company does not have enough cash to pay it back. Negotiations with bond holders failed in a...

Clinical Trial

06.03.2012

Munich – German 4SC AG jumped 39% to €2.05/share after oncology drug candidate resminostat met the primary endpoint of at least a 20% progression-free survival rate in a Phase II trial to treat patients with hepatocellular...

Editorial

06.03.2012

The start of 2012 witnessed the tides turning in favour of small and mid-cap names in the European Life Sciences sector. Major global biotechnology indices like the NBI, BTK, and BIOTK are up over 15% year to date. The pace of...

Displaying results 1 to 10 out of 1982

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive/article/ec-launches-bioeconomy-strategy.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.97 EUR11.43%
  • PROSENSA (NL)10.24 USD5.89%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK5.71%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • STENTYS (F)7.26 EUR-12.32%

TOP

  • WILEX (D)2.70 EUR229.3%
  • NEUROVIVE PHARMACEUTICAL AB (S)74.00 SEK52.6%
  • Allergy Therapeutics (UK)20.00 GBP34.4%

FLOP

  • HYBRIGENICS (F)1.68 EUR-29.7%
  • GW PHARMACEUTICALS (UK)418.50 GBP-20.1%
  • PHARMING (NL)0.44 EUR-20.0%

TOP

  • SANTHERA (CH)59.90 CHF2836.3%
  • GW PHARMACEUTICALS (UK)418.50 GBP634.2%
  • PAION (D)2.50 EUR284.6%

FLOP

  • EVOCUTIS (UK)0.21 GBP-92.7%
  • CYTOS (CH)0.27 CHF-92.0%
  • THROMBOGENICS (B)9.16 EUR-70.3%

No liability assumed, Date: 31.07.2014


Current issue

All issues

Product of the week

Products